title: Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort.
abstract: Introduction. Concern regarding overtreatment of prostate cancer (CaP) is leading to increased attention on active surveillance (AS). This study examined CaP survivors on AS and compared secondary treatment patterns and overall survival by race/ethnicity. Methods. The study population consisted of CaP patients self-classified as black or white followed on AS in the Center for Prostate Disease Research (CPDR) multicenter national database between 1989 and 2008. Secondary treatment included radical prostatectomy (RP), external beam radiation therapy or brachytherapy (EBRT-Br), and hormone therapy (HT). Secondary treatment patterns and overall survival were compared by race/ethnicity. Results. Among 886 eligible patients, 21% were black. Despite racial differences in risk characteristics and secondary treatment patterns, overall survival was comparable across race. RP following AS was associated with the longest overall survival. Conclusion. Racial disparity in overall survival was not observed in this military health care beneficiary cohort with an equal access to health care.
authors.affiliation: Center for Prostate Disease Research, Department of Defense, Rockville, MD 20852, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Cullen
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Brassell
authors.forename: Yongmei
authors.initials: Y
authors.lastname: Chen
authors.forename: Christopher
authors.initials: C
authors.lastname: Porter
authors.forename: James
authors.initials: J
authors.lastname: L'esperance
authors.forename: Timothy
authors.initials: T
authors.lastname: Brand
authors.forename: David G
authors.initials: DG
authors.lastname: McLeod
references.citation: Urology. 2008 Jan;71(1):151-5
references.pmid: 18242385
references.citation: Cancer. 2010 Jun 1;116(11):2698-706
references.pmid: 20309847
references.citation: Prostate. 2010 Jul 1;70(10):1102-9
references.pmid: 20503395
references.citation: JAMA. 1998 Sep 16;280(11):969-74
references.pmid: 9749478
references.citation: Nat Rev Urol. 2010 Sep;7(9):480-1
references.pmid: 20818323
references.citation: Cancer. 2010 Oct 15;116(20):4711-7
references.pmid: 20589748
references.citation: J Natl Cancer Inst. 2009 Jul 15;101(14):984-92
references.pmid: 19584328
references.citation: Urology. 2010 Dec;76(6):1409-13
references.pmid: 20888034
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1069-74
references.pmid: 20100957
references.citation: BMC Cancer. 2010 Apr 19;10:152
references.pmid: 20403178
references.citation: BJU Int. 2010 Aug;106(3):322-8
references.pmid: 20553251
references.citation: Urol Oncol. 2009 Sep-Oct;27(5):562-9
references.pmid: 19720304
references.citation: Urology. 2009 Dec;74(6):1296-302
references.pmid: 19962532
references.citation: Cancer. 2011 Jun 1;117(11):2520-9
references.pmid: 24048800
references.citation: Prostate. 2011 Jun 15;71(9):985-97
references.pmid: 21541975
references.citation: Am J Mens Health. 2010 Sep;4(3):189-206
references.pmid: 20483872
references.citation: J Health Care Poor Underserved. 2010 Feb;21(1):144-60
references.pmid: 20173261
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Cancer. 2011 Mar 1;117(5):1080-8
references.pmid: 21351084
references.citation: J Urol. 2010 May;183(5):1792-6
references.pmid: 20299055